• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Benign Prostatic Hyperplasia Treatment Market Analysis

    ID: MRFR/HC/10317-HCR
    128 Pages
    Kinjoll Dey
    October 2025

    Benign Prostatic Hyperplasia Treatment Market Research Report Information By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), By Therapy (Mono Drug Therapy and Combination Drug Therapy), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) – Market Forecast Till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Benign Prostatic Hyperplasia Treatment Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Analysis

    In-depth Analysis of Benign Prostatic Hyperplasia Treatment Market Industry Landscape

    In addition to healthcare economics and demographic trends, technological advancements and regulatory considerations impact the benign prostatic hyperplasia treatment market. The aging of the world's population, especially in developed areas, is a major factor, given that BPH is primarily associated with aging. This increases the need for efficacious treatment alternatives. Developments in drugs, negligibly obtrusive methodology, and laser treatments are instances of mechanical advances in the treatment of BPH that significantly affect market elements. This outcomes in a wide exhibit of mediations, outfitting clinical professionals with a sweeping arrangement of assets to address the prerequisites of patients. The dynamics of the BPH treatment market are notably influenced by regulatory factors, as rigorous approval procedures guarantee both safety and effectiveness. Standards adherence impacts benign prostatic hyperplasia treatment market strategies, product development, clinical trials, and entry strategies, thereby bolstering the trustworthiness and credibility of treatment options for BPH. Market dynamics are substantially impacted by economic factors, healthcare expenditure, and reimbursement policies. Adoption rates are likewise influenced by cost-effectiveness and accessibility. Prominent figures in the market innovate interventions and enhance reimbursement policies. Collaboration in healthcare and globalization in the BPH treatment market facilitate the exchange of knowledge, increase the availability of treatments, and advance a standardized approach to care. The dynamics of the BPH treatment market are influenced by patient preferences and quality of life factors, which place a premium on minimally invasive procedures and medications that provide effective symptom relief and facilitate a speedy recovery. In contrast to other healthcare sectors, the impact of environmental factors, including sustainability, on the BPH treatment market is comparatively limited. However, the advancement of energy-efficient technologies signifies a more extensive dedication to accountable healthcare. The Coronavirus pandemic significantly affects the BPH treatment market, as the need might arise for mediations that decline emergency clinic stays and proposition short term other options.

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Get In Touch

    Leave a Comment

    FAQs

    What is the current valuation of the Benign Prostatic Hyperplasia Treatment Market?

    The market valuation was 12.45 USD Billion in 2024.

    What is the projected market size for the Benign Prostatic Hyperplasia Treatment Market by 2035?

    The market is projected to reach 22.44 USD Billion by 2035.

    What is the expected CAGR for the Benign Prostatic Hyperplasia Treatment Market during the forecast period?

    The expected CAGR for the market from 2025 to 2035 is 5.5%.

    Which therapeutic classes are leading in the Benign Prostatic Hyperplasia Treatment Market?

    Alpha Blockers and 5-Alpha Reductase Inhibitors are leading therapeutic classes, with valuations of 6.73 and 4.52 USD Billion respectively by 2035.

    What are the projected revenues for Mono Drug Therapy and Combination Drug Therapy by 2035?

    Both Mono Drug Therapy and Combination Drug Therapy are projected to reach 11.22 USD Billion by 2035.

    Who are the key players in the Benign Prostatic Hyperplasia Treatment Market?

    Key players include Astellas Pharma, Boehringer Ingelheim, Eli Lilly and Company, and others.

    Market Summary

    As per MRFR analysis, the Benign Prostatic Hyperplasia Treatment Market was estimated at 12.45 USD Billion in 2024. The market is projected to grow from 13.13 USD Billion in 2025 to 22.44 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.5 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Benign Prostatic Hyperplasia Treatment Market is experiencing a transformative shift towards innovative and patient-centric solutions.

    • The market is witnessing a rise in minimally invasive techniques, enhancing patient recovery and satisfaction.
    • North America remains the largest market, driven by advanced healthcare infrastructure and high treatment adoption rates.
    • In the Asia-Pacific region, the market is growing rapidly, fueled by increasing awareness and healthcare access.
    • Key market drivers include the aging population and advancements in treatment modalities, particularly in Alpha Blockers and Combination Drug Therapy segments.

    Market Size & Forecast

    2024 Market Size 12.45 (USD Billion)
    2035 Market Size 22.44 (USD Billion)
    CAGR (2025 - 2035) 5.5%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>Astellas Pharma (JP), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GlaxoSmithKline (GB), Merck & Co. (US), Pfizer Inc. (US), Sanofi (FR), Teva Pharmaceutical Industries (IL), AbbVie Inc. (US)</p>

    Market Trends

    The Benign Prostatic Hyperplasia Treatment Market is currently experiencing notable transformations driven by advancements in medical technology and an increasing awareness of prostate health. As the global population ages, the prevalence of benign prostatic hyperplasia (BPH) rises, prompting a surge in demand for effective treatment options. This market encompasses a variety of therapeutic approaches, including pharmacological treatments, minimally invasive procedures, and surgical interventions. The growing emphasis on patient-centered care is influencing the development of innovative therapies that prioritize safety and efficacy, thereby enhancing the overall treatment experience for individuals affected by BPH. Moreover, the landscape of the Benign Prostatic Hyperplasia Treatment Market is shaped by ongoing research and development efforts aimed at improving existing therapies and introducing novel solutions. Collaboration among pharmaceutical companies, healthcare providers, and research institutions appears to be fostering a dynamic environment conducive to innovation. Additionally, the integration of digital health technologies, such as telemedicine and mobile health applications, is likely to enhance patient engagement and adherence to treatment regimens. As the market evolves, stakeholders must remain attuned to emerging trends and shifts in patient preferences to effectively address the diverse needs of those living with benign prostatic hyperplasia.

    Rise of Minimally Invasive Techniques

    The trend towards minimally invasive techniques in the Benign Prostatic Hyperplasia Treatment Market is gaining traction. These methods, which include laser therapies and transurethral procedures, offer patients reduced recovery times and lower complication rates compared to traditional surgical options. As awareness of these benefits spreads, more patients are likely to opt for these alternatives, influencing market dynamics.

    Increased Focus on Patient-Centric Solutions

    There is a growing emphasis on patient-centric solutions within the Benign Prostatic Hyperplasia Treatment Market. Healthcare providers are increasingly prioritizing treatments that not only address the medical aspects of BPH but also consider the quality of life of patients. This shift is prompting the development of therapies that are tailored to individual needs, potentially leading to improved patient satisfaction and adherence.

    Integration of Digital Health Technologies

    The integration of digital health technologies is transforming the Benign Prostatic Hyperplasia Treatment Market. Telemedicine and mobile health applications are becoming essential tools for patient management, allowing for remote consultations and monitoring. This trend may enhance accessibility to care and facilitate better communication between patients and healthcare providers, ultimately improving treatment outcomes.

    <p>The increasing prevalence of benign prostatic hyperplasia among aging populations is driving a notable shift towards innovative treatment modalities, reflecting a growing recognition of the need for effective management strategies.</p>

    National Institutes of Health (NIH)

    Benign Prostatic Hyperplasia Treatment Market Market Drivers

    Rising Healthcare Expenditure

    The increasing healthcare expenditure across various regions is significantly influencing the Benign Prostatic Hyperplasia Treatment Market. As governments and private sectors allocate more resources to healthcare, there is a corresponding rise in the availability of advanced treatment options for BPH. This trend is particularly evident in developed economies, where healthcare budgets are expanding to accommodate innovative therapies and technologies. The willingness of patients to invest in their health, coupled with insurance coverage for BPH treatments, is likely to enhance market growth. Consequently, the Benign Prostatic Hyperplasia Treatment Market stands to benefit from this upward trajectory in healthcare spending, as more individuals seek timely and effective interventions.

    Advancements in Treatment Modalities

    Innovations in treatment modalities are playing a crucial role in shaping the Benign Prostatic Hyperplasia Treatment Market. The introduction of new pharmacological agents, such as alpha-blockers and 5-alpha-reductase inhibitors, has expanded the therapeutic options available for patients. Additionally, minimally invasive procedures, including laser therapy and transurethral resection of the prostate, are gaining traction due to their effectiveness and reduced recovery times. The market is anticipated to benefit from ongoing research and development efforts aimed at enhancing treatment efficacy and patient outcomes. As these advancements continue to emerge, they are likely to attract more patients seeking effective solutions for BPH, thereby propelling the growth of the Benign Prostatic Hyperplasia Treatment Market.

    Growing Awareness and Education Initiatives

    The Benign Prostatic Hyperplasia Treatment Market is witnessing a surge in growth driven by increased awareness and education initiatives surrounding BPH. Healthcare organizations and advocacy groups are actively promoting information about the condition, its symptoms, and available treatment options. This heightened awareness is encouraging men to seek medical advice and treatment sooner, which is crucial for effective management of BPH. Educational campaigns are also addressing the stigma associated with prostate health, leading to a more open dialogue about the condition. As awareness continues to rise, it is expected that more patients will engage with healthcare providers, thereby contributing to the expansion of the Benign Prostatic Hyperplasia Treatment Market.

    Aging Population and Rising Incidence of BPH

    The Benign Prostatic Hyperplasia Treatment Market is experiencing growth due to the increasing prevalence of BPH among the aging population. As men age, the likelihood of developing BPH rises significantly, with studies indicating that nearly 50% of men aged 50 and older may experience symptoms. This demographic shift is expected to drive demand for effective treatment options, including medications and surgical interventions. The market is projected to expand as healthcare providers seek to address the needs of this growing patient population. Furthermore, the rising awareness of BPH and its impact on quality of life is likely to encourage more individuals to seek treatment, thereby contributing to the overall growth of the Benign Prostatic Hyperplasia Treatment Market.

    Integration of Telemedicine in BPH Management

    The integration of telemedicine into the management of BPH is emerging as a transformative factor in the Benign Prostatic Hyperplasia Treatment Market. Telehealth services are facilitating remote consultations, allowing patients to receive timely medical advice without the need for in-person visits. This is particularly beneficial for individuals in rural or underserved areas, where access to specialized care may be limited. The convenience and efficiency of telemedicine are likely to encourage more patients to seek treatment for BPH, thus expanding the market. As healthcare systems continue to embrace digital solutions, the Benign Prostatic Hyperplasia Treatment Market is poised for growth, driven by the increasing adoption of telehealth technologies.

    Market Segment Insights

    By Therapeutic Class: Alpha Blockers (Largest) vs. 5-Alpha Reductase Inhibitors (Fastest-Growing)

    <p>In the Benign Prostatic Hyperplasia (BPH) treatment market, Alpha Blockers emerge as the largest segment, commanding a significant portion of the market share. These medications work by relaxing the muscles in the prostate and bladder neck, facilitating easier urination, which makes them a preferred choice among healthcare providers. Conversely, 5-Alpha Reductase Inhibitors, while currently smaller in market share relative to Alpha Blockers, are witnessing accelerated growth due to their effectiveness in reducing prostate size and long-term treatment benefits. This growth is further fueled by increased awareness and diagnosis of BPH among the aging population. The growth trends in the therapeutic class for BPH treatment are driven by several factors, including advancements in treatment efficacy and the widening acceptance of newer medications. As patients and healthcare providers seek more effective long-term solutions, the demand for 5-Alpha Reductase Inhibitors is expected to rise significantly. Moreover, ongoing research and developments in drug formulations are likely to enhance the utility of these therapeutics, thereby positioning them as a robust option in BPH management. Increased focus on patient outcomes and satisfaction will continue to dictate the success of this segment in the coming years.</p>

    <p>Alpha Blockers (Dominant) vs. 5-Alpha Reductase Inhibitors (Emerging)</p>

    <p>Alpha Blockers currently hold a dominant position in the Benign Prostatic Hyperplasia treatment landscape, characterized by a broad acceptance among both patients and healthcare providers. These medications provide rapid relief of urinary symptoms, appealing to patients seeking immediate improvements. In contrast, 5-Alpha Reductase Inhibitors are emerging as a vital segment due to their long-term impact on prostate size and symptoms. Their slower onset acts to differentiate them from Alpha Blockers, but the therapeutic effectiveness in managing BPH long-term is becoming increasingly recognized. Both segments offer unique benefits, with Alpha Blockers leading in immediate relief while 5-Alpha Reductase Inhibitors are gaining traction for their sustained therapeutic benefits.</p>

    By Therapy: Mono Drug Therapy (Largest) vs. Combination Drug Therapy (Fastest-Growing)

    <p>In the Benign Prostatic Hyperplasia (BPH) Treatment Market, Mono Drug Therapy stands out as the largest segment, capturing a significant share of the market. This approach, utilizing single-agent drugs, has been a traditional choice among healthcare providers, thereby establishing a strong foothold. The efficacy and simplicity of mono therapies contribute to their ongoing popularity, particularly for patients with mild to moderate BPH symptoms. On the other hand, Combination Drug Therapy is emerging as the fastest-growing segment within this market. The combination of different therapeutic agents allows for enhanced efficacy, particularly in more severe cases of BPH. As patient preferences shift towards personalized medicine, the demand for combination therapies is on the rise. Increased awareness of treatment options and the push for holistic patient care are significant drivers of this growth trend.</p>

    <p>Therapy: Mono Drug (Dominant) vs. Combination Drug (Emerging)</p>

    <p>Mono Drug Therapy is characterized by its straightforward approach, employing a single medication to alleviate the symptoms of BPH. This method is favored for its simplicity and controlled dosing, making it a reliable option for a substantial number of patients. Its dominance in the market is largely attributed to established treatments and a solid understanding of their mechanisms. However, Combination Drug Therapy is emerging strongly by addressing a broader range of symptoms more effectively than monotreatment. This segment combines multiple agents to tackle the complexity of BPH, thereby appealing to patients with varying severity levels and coexisting conditions. As clinicians seek to optimize therapeutic outcomes, this segment's tailored approach is expected to garner increasing acceptance, positioning it as a noteworthy competitor to mono therapies.</p>

    Get more detailed insights about Benign Prostatic Hyperplasia Treatment Market Research Report—Global Forecast till 2035

    Regional Insights

    North America : Leading Market for Treatments

    North America is the largest market for Benign Prostatic Hyperplasia (BPH) treatments, accounting for approximately 45% of the global market share. The region's growth is driven by an aging population, increasing prevalence of BPH, and advancements in treatment options. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring the availability of innovative therapies and medications. The United States is the primary contributor to this market, with significant investments from key players such as Pfizer Inc., Merck & Co., and AbbVie Inc. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all striving to capture market share through innovative solutions and effective marketing strategies. The presence of robust healthcare infrastructure also supports the growth of BPH treatments in this region.

    Europe : Regulatory Support and Innovation

    Europe is the second-largest market for Benign Prostatic Hyperplasia treatments, holding around 30% of the global market share. The region's growth is fueled by increasing awareness of BPH, a rising geriatric population, and favorable regulatory frameworks that encourage the development of new therapies. The European Medicines Agency (EMA) plays a crucial role in ensuring the safety and efficacy of treatments, which boosts consumer confidence and market demand. Leading countries in this market include Germany, France, and the UK, where healthcare systems are increasingly adopting advanced treatment options. Major players like Astellas Pharma and Boehringer Ingelheim are actively involved in research and development, contributing to a competitive landscape that fosters innovation. The presence of well-established healthcare networks further enhances the accessibility of BPH treatments across Europe.

    Asia-Pacific : Emerging Market Potential

    The Asia-Pacific region is witnessing significant growth in the Benign Prostatic Hyperplasia treatment market, accounting for approximately 15% of the global share. Factors such as increasing urbanization, rising healthcare expenditure, and a growing awareness of prostate health are driving demand. Additionally, government initiatives aimed at improving healthcare access and affordability are expected to further boost market growth in the coming years. Countries like Japan, China, and India are leading the charge in this market, with a mix of local and international players vying for market share. Companies such as Eli Lilly and Teva Pharmaceutical Industries are focusing on expanding their presence through strategic partnerships and innovative product offerings. The competitive landscape is evolving, with an increasing number of generic medications entering the market, providing more options for patients.

    Middle East and Africa : Untapped Market Opportunities

    The Middle East and Africa region represents an emerging market for Benign Prostatic Hyperplasia treatments, holding about 10% of the global market share. The growth in this region is driven by increasing awareness of prostate health, rising healthcare investments, and a growing population of elderly men. However, challenges such as limited access to healthcare facilities and varying regulatory environments can hinder market expansion. Countries like South Africa and the UAE are at the forefront of this market, with increasing healthcare initiatives aimed at improving access to treatments. Key players, including GlaxoSmithKline and Sanofi, are exploring opportunities to expand their footprint in this region. The competitive landscape is characterized by a mix of multinational corporations and local firms, all striving to meet the growing demand for effective BPH treatments.

    Key Players and Competitive Insights

    The Benign Prostatic Hyperplasia (BPH) Treatment Market is characterized by a dynamic competitive landscape, driven by an increasing prevalence of BPH among aging populations and a growing demand for effective therapeutic options. Key players such as Astellas Pharma (Japan), Merck & Co. (US), and AbbVie Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Astellas Pharma (Japan) focuses on developing novel therapies, while Merck & Co. (US) emphasizes expanding its product portfolio through strategic acquisitions. AbbVie Inc. (US) is actively pursuing collaborations to enhance its research capabilities, thereby shaping a competitive environment that prioritizes innovation and strategic alliances.

    The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. This trend is indicative of a broader strategy among key players to respond to regional demands and regulatory requirements, thereby solidifying their competitive positions. The collective influence of these companies fosters a competitive atmosphere where innovation and operational excellence are paramount.

    In August 2025, Astellas Pharma (Japan) announced the initiation of a Phase III clinical trial for its new BPH treatment, which aims to provide a more effective solution for patients. This strategic move underscores Astellas' commitment to innovation and its focus on addressing unmet medical needs in the BPH treatment landscape. The trial's outcomes could significantly impact the company's market positioning and contribute to its long-term growth strategy.

    In September 2025, Merck & Co. (US) completed the acquisition of a biotechnology firm specializing in urology, which is expected to enhance its BPH treatment portfolio. This acquisition reflects Merck's strategy to bolster its research and development capabilities, allowing for the introduction of cutting-edge therapies. The integration of new technologies and expertise could potentially accelerate the development of innovative solutions for BPH, thereby strengthening Merck's competitive edge.

    In July 2025, AbbVie Inc. (US) entered into a strategic partnership with a leading digital health company to develop a telehealth platform aimed at improving patient access to BPH treatments. This initiative highlights AbbVie's focus on digital transformation and patient-centric care, which are increasingly vital in today's healthcare landscape. By leveraging technology, AbbVie aims to enhance patient engagement and streamline treatment pathways, positioning itself favorably in a competitive market.

    As of October 2025, the BPH treatment market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in therapeutic development. Strategic alliances are becoming increasingly important, as companies seek to combine resources and expertise to drive innovation. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment options, and reliable supply chains. This shift suggests that companies prioritizing research and development, alongside strategic partnerships, will be better positioned to thrive in the evolving landscape.

    Key Companies in the Benign Prostatic Hyperplasia Treatment Market market include

    Industry Developments

    October 2020 A merger between Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited was announced; it is anticipated to close in 2023. The goal of this merger is to establish a global leader in the creation and marketing of cutting-edge therapies for people with benign prostatic hyperplasia (BPH).

    Future Outlook

    Benign Prostatic Hyperplasia Treatment Market Future Outlook

    <p>The Benign Prostatic Hyperplasia Treatment Market is projected to grow at a 5.5% CAGR from 2024 to 2035, driven by increasing prevalence and advancements in treatment options.</p>

    New opportunities lie in:

    • <p>Development of telehealth platforms for remote patient monitoring</p>
    • <p>Investment in minimally invasive surgical technologies</p>
    • <p>Expansion of personalized medicine approaches for treatment optimization</p>

    <p>By 2035, the market is expected to be robust, reflecting significant advancements and increased patient access.</p>

    Market Segmentation

    Benign Prostatic Hyperplasia Treatment Market Therapy Outlook

    • Mono Drug Therapy
    • Combination Drug Therapy

    Benign Prostatic Hyperplasia Treatment Market Therapeutic Class Outlook

    • Alpha Blockers
    • 5- Alpha Reductase Inhibitors
    • Phosphodiesterase-5 Inhibitors
    • Others

    Report Scope

    MARKET SIZE 202412.45(USD Billion)
    MARKET SIZE 202513.13(USD Billion)
    MARKET SIZE 203522.44(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)5.5% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesEmergence of minimally invasive therapies enhances patient compliance in the Benign Prostatic Hyperplasia Treatment Market.
    Key Market DynamicsRising demand for minimally invasive procedures drives innovation in Benign Prostatic Hyperplasia treatment options and technologies.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    What is the current valuation of the Benign Prostatic Hyperplasia Treatment Market?

    The market valuation was 12.45 USD Billion in 2024.

    What is the projected market size for the Benign Prostatic Hyperplasia Treatment Market by 2035?

    The market is projected to reach 22.44 USD Billion by 2035.

    What is the expected CAGR for the Benign Prostatic Hyperplasia Treatment Market during the forecast period?

    The expected CAGR for the market from 2025 to 2035 is 5.5%.

    Which therapeutic classes are leading in the Benign Prostatic Hyperplasia Treatment Market?

    Alpha Blockers and 5-Alpha Reductase Inhibitors are leading therapeutic classes, with valuations of 6.73 and 4.52 USD Billion respectively by 2035.

    What are the projected revenues for Mono Drug Therapy and Combination Drug Therapy by 2035?

    Both Mono Drug Therapy and Combination Drug Therapy are projected to reach 11.22 USD Billion by 2035.

    Who are the key players in the Benign Prostatic Hyperplasia Treatment Market?

    Key players include Astellas Pharma, Boehringer Ingelheim, Eli Lilly and Company, and others.

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Therapeutic Class (USD Billion)
      2. | | 4.1.1 Alpha Blockers
      3. | | 4.1.2 5- Alpha Reductase Inhibitors
      4. | | 4.1.3 Phosphodiesterase-5 Inhibitors
      5. | | 4.1.4 Others
      6. | 4.2 Healthcare, BY Therapy (USD Billion)
      7. | | 4.2.1 Mono Drug Therapy
      8. | | 4.2.2 Combination Drug Therapy
      9. | 4.3 Healthcare, BY Region (USD Billion)
      10. | | 4.3.1 North America
      11. | | | 4.3.1.1 US
      12. | | | 4.3.1.2 Canada
      13. | | 4.3.2 Europe
      14. | | | 4.3.2.1 Germany
      15. | | | 4.3.2.2 UK
      16. | | | 4.3.2.3 France
      17. | | | 4.3.2.4 Russia
      18. | | | 4.3.2.5 Italy
      19. | | | 4.3.2.6 Spain
      20. | | | 4.3.2.7 Rest of Europe
      21. | | 4.3.3 APAC
      22. | | | 4.3.3.1 China
      23. | | | 4.3.3.2 India
      24. | | | 4.3.3.3 Japan
      25. | | | 4.3.3.4 South Korea
      26. | | | 4.3.3.5 Malaysia
      27. | | | 4.3.3.6 Thailand
      28. | | | 4.3.3.7 Indonesia
      29. | | | 4.3.3.8 Rest of APAC
      30. | | 4.3.4 South America
      31. | | | 4.3.4.1 Brazil
      32. | | | 4.3.4.2 Mexico
      33. | | | 4.3.4.3 Argentina
      34. | | | 4.3.4.4 Rest of South America
      35. | | 4.3.5 MEA
      36. | | | 4.3.5.1 GCC Countries
      37. | | | 4.3.5.2 South Africa
      38. | | | 4.3.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 Astellas Pharma (JP)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Boehringer Ingelheim (DE)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Eli Lilly and Company (US)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 GlaxoSmithKline (GB)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 Merck & Co. (US)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 Pfizer Inc. (US)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 Sanofi (FR)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 Teva Pharmaceutical Industries (IL)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | | 5.2.9 AbbVie Inc. (US)
      65. | | | 5.2.9.1 Financial Overview
      66. | | | 5.2.9.2 Products Offered
      67. | | | 5.2.9.3 Key Developments
      68. | | | 5.2.9.4 SWOT Analysis
      69. | | | 5.2.9.5 Key Strategies
      70. | 5.3 Appendix
      71. | | 5.3.1 References
      72. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY THERAPEUTIC CLASS
      4. | 6.4 US MARKET ANALYSIS BY THERAPY
      5. | 6.5 CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS
      6. | 6.6 CANADA MARKET ANALYSIS BY THERAPY
      7. | 6.7 EUROPE MARKET ANALYSIS
      8. | 6.8 GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS
      9. | 6.9 GERMANY MARKET ANALYSIS BY THERAPY
      10. | 6.10 UK MARKET ANALYSIS BY THERAPEUTIC CLASS
      11. | 6.11 UK MARKET ANALYSIS BY THERAPY
      12. | 6.12 FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS
      13. | 6.13 FRANCE MARKET ANALYSIS BY THERAPY
      14. | 6.14 RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
      15. | 6.15 RUSSIA MARKET ANALYSIS BY THERAPY
      16. | 6.16 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
      17. | 6.17 ITALY MARKET ANALYSIS BY THERAPY
      18. | 6.18 SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS
      19. | 6.19 SPAIN MARKET ANALYSIS BY THERAPY
      20. | 6.20 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS
      21. | 6.21 REST OF EUROPE MARKET ANALYSIS BY THERAPY
      22. | 6.22 APAC MARKET ANALYSIS
      23. | 6.23 CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS
      24. | 6.24 CHINA MARKET ANALYSIS BY THERAPY
      25. | 6.25 INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS
      26. | 6.26 INDIA MARKET ANALYSIS BY THERAPY
      27. | 6.27 JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS
      28. | 6.28 JAPAN MARKET ANALYSIS BY THERAPY
      29. | 6.29 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS
      30. | 6.30 SOUTH KOREA MARKET ANALYSIS BY THERAPY
      31. | 6.31 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
      32. | 6.32 MALAYSIA MARKET ANALYSIS BY THERAPY
      33. | 6.33 THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS
      34. | 6.34 THAILAND MARKET ANALYSIS BY THERAPY
      35. | 6.35 INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS
      36. | 6.36 INDONESIA MARKET ANALYSIS BY THERAPY
      37. | 6.37 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS
      38. | 6.38 REST OF APAC MARKET ANALYSIS BY THERAPY
      39. | 6.39 SOUTH AMERICA MARKET ANALYSIS
      40. | 6.40 BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS
      41. | 6.41 BRAZIL MARKET ANALYSIS BY THERAPY
      42. | 6.42 MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS
      43. | 6.43 MEXICO MARKET ANALYSIS BY THERAPY
      44. | 6.44 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS
      45. | 6.45 ARGENTINA MARKET ANALYSIS BY THERAPY
      46. | 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
      47. | 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPY
      48. | 6.48 MEA MARKET ANALYSIS
      49. | 6.49 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS
      50. | 6.50 GCC COUNTRIES MARKET ANALYSIS BY THERAPY
      51. | 6.51 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS
      52. | 6.52 SOUTH AFRICA MARKET ANALYSIS BY THERAPY
      53. | 6.53 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS
      54. | 6.54 REST OF MEA MARKET ANALYSIS BY THERAPY
      55. | 6.55 KEY BUYING CRITERIA OF HEALTHCARE
      56. | 6.56 RESEARCH PROCESS OF MRFR
      57. | 6.57 DRO ANALYSIS OF HEALTHCARE
      58. | 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      59. | 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      60. | 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
      61. | 6.61 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE)
      62. | 6.62 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion)
      63. | 6.63 HEALTHCARE, BY THERAPY, 2024 (% SHARE)
      64. | 6.64 HEALTHCARE, BY THERAPY, 2024 TO 2035 (USD Billion)
      65. | 6.65 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY THERAPY, 2025-2035 (USD Billion)
      6. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      7. | | 7.3.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      8. | | 7.3.2 BY THERAPY, 2025-2035 (USD Billion)
      9. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      10. | | 7.4.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      11. | | 7.4.2 BY THERAPY, 2025-2035 (USD Billion)
      12. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      13. | | 7.5.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      14. | | 7.5.2 BY THERAPY, 2025-2035 (USD Billion)
      15. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      16. | | 7.6.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      17. | | 7.6.2 BY THERAPY, 2025-2035 (USD Billion)
      18. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      19. | | 7.7.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      20. | | 7.7.2 BY THERAPY, 2025-2035 (USD Billion)
      21. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      22. | | 7.8.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      23. | | 7.8.2 BY THERAPY, 2025-2035 (USD Billion)
      24. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      25. | | 7.9.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      26. | | 7.9.2 BY THERAPY, 2025-2035 (USD Billion)
      27. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      28. | | 7.10.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      29. | | 7.10.2 BY THERAPY, 2025-2035 (USD Billion)
      30. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      31. | | 7.11.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      32. | | 7.11.2 BY THERAPY, 2025-2035 (USD Billion)
      33. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      34. | | 7.12.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      35. | | 7.12.2 BY THERAPY, 2025-2035 (USD Billion)
      36. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      37. | | 7.13.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      38. | | 7.13.2 BY THERAPY, 2025-2035 (USD Billion)
      39. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      40. | | 7.14.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      41. | | 7.14.2 BY THERAPY, 2025-2035 (USD Billion)
      42. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      43. | | 7.15.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      44. | | 7.15.2 BY THERAPY, 2025-2035 (USD Billion)
      45. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      46. | | 7.16.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      47. | | 7.16.2 BY THERAPY, 2025-2035 (USD Billion)
      48. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      49. | | 7.17.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      50. | | 7.17.2 BY THERAPY, 2025-2035 (USD Billion)
      51. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      52. | | 7.18.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      53. | | 7.18.2 BY THERAPY, 2025-2035 (USD Billion)
      54. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      55. | | 7.19.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      56. | | 7.19.2 BY THERAPY, 2025-2035 (USD Billion)
      57. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      58. | | 7.20.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      59. | | 7.20.2 BY THERAPY, 2025-2035 (USD Billion)
      60. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      61. | | 7.21.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      62. | | 7.21.2 BY THERAPY, 2025-2035 (USD Billion)
      63. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.22.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      65. | | 7.22.2 BY THERAPY, 2025-2035 (USD Billion)
      66. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      67. | | 7.23.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      68. | | 7.23.2 BY THERAPY, 2025-2035 (USD Billion)
      69. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      70. | | 7.24.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      71. | | 7.24.2 BY THERAPY, 2025-2035 (USD Billion)
      72. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      73. | | 7.25.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      74. | | 7.25.2 BY THERAPY, 2025-2035 (USD Billion)
      75. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      76. | | 7.26.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      77. | | 7.26.2 BY THERAPY, 2025-2035 (USD Billion)
      78. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      79. | | 7.27.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      80. | | 7.27.2 BY THERAPY, 2025-2035 (USD Billion)
      81. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      82. | | 7.28.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      83. | | 7.28.2 BY THERAPY, 2025-2035 (USD Billion)
      84. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      85. | | 7.29.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      86. | | 7.29.2 BY THERAPY, 2025-2035 (USD Billion)
      87. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      88. | | 7.30.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
      89. | | 7.30.2 BY THERAPY, 2025-2035 (USD Billion)
      90. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      91. | | 7.31.1
      92. | 7.32 ACQUISITION/PARTNERSHIP
      93. | | 7.32.1

    Benign Prostatic Hyperplasia Treatment aMarket Segmentation

    Benign Prostatic Hyperplasia Treatment Therapeutics Class Outlook (USD Billion, 2018-2032)

    Alpha blockersa

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment Therapy Outlook (USD Billion, 2018-2032)

    Mono drug therapy

    Combination drug therapy

    Benign Prostatic Hyperplasia Treatment Regional Outlook (USD Billion, 2018-2032)

    North America Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    US Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Canada Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Europe Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Germany Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    France Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    UK Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Italy Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Spain Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Rest Of Europe Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Asia-Pacific Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    China Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Japan Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    India Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Australia Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Rest of the World Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Middle East Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Africa Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

    Latin America Outlook (USD Billion, 2018-2032)

    Benign Prostatic Hyperplasia Treatment by Therapeutics Class

    Alpha blockers

    5- alpha reductase inhibitors

    Phosphodiesterase-5 inhibitors

    Others

    Benign Prostatic Hyperplasia Treatment by Therapy

    Mono drug therapy

    Combination drug therapy

     

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓